Similarly, Gide et al. analyzed baseline melanoma dissociated tissue from patients treated with anti-PD1 monotherapy or combined immunotherapy (anti-PD1 + anti-CTLA4) identifying the subset EOMES + CD69 + CD45RO + of effector memory T cells associated with greater tumor shrinkage in both therapies [81]. This evidence concerns the gene CTLA4 and melanoma.